AIMS: Heart failure (HF) is reported to have an essentially malignant prognosis that can be modified by several interventions. Most outcome data on HF are available from randomized controlled treatment trials and longitudinal epidemiological studies. However, for a number of reasons, neither type of study have, to date, provided generalizable data on HF mortality. Furthermore, data on the prognosis of borderline left ventricular systolic dysfunction (LVSD) are even more limited. METHODS AND RESULTS: ECHOES (Echocardiographic Heart of England Screening Study) screened a total of 6,162 patients from a total of 10,161 invited (61% response rate). Patients were randomly selected from four pre-specified cohorts: the general population, diuretic users, those with a prior clinical label of HF, and a population with risk factors for HF, to identify the prevalence of HF and LVSD based on clinical assessment, ECG, and echocardiography. Causes of death during a 5-9 year follow-up period were recorded from routine mortality statistics. The 5-year survival rate of the general population was 93%, compared with 69% of those with LVSD without HF, 62% with HF and no LVSD, and 53% with HF plus LVSD. Survival improved significantly with increasing ejection fraction (EF) (log rank test for trend, chi(2) = 534.5, 1, P < 0.0001). CONCLUSION: The ECHOES mortality data confirm the poor prognosis of patients suffering prevalent HF across the community with a mortality risk estimate of 9% per year. Borderline systolic dysfunction (EF 40-50%) on echocardiography carries a poor prognosis.
AIMS: Heart failure (HF) is reported to have an essentially malignant prognosis that can be modified by several interventions. Most outcome data on HF are available from randomized controlled treatment trials and longitudinal epidemiological studies. However, for a number of reasons, neither type of study have, to date, provided generalizable data on HF mortality. Furthermore, data on the prognosis of borderline left ventricular systolic dysfunction (LVSD) are even more limited. METHODS AND RESULTS: ECHOES (Echocardiographic Heart of England Screening Study) screened a total of 6,162 patients from a total of 10,161 invited (61% response rate). Patients were randomly selected from four pre-specified cohorts: the general population, diuretic users, those with a prior clinical label of HF, and a population with risk factors for HF, to identify the prevalence of HF and LVSD based on clinical assessment, ECG, and echocardiography. Causes of death during a 5-9 year follow-up period were recorded from routine mortality statistics. The 5-year survival rate of the general population was 93%, compared with 69% of those with LVSD without HF, 62% with HF and no LVSD, and 53% with HF plus LVSD. Survival improved significantly with increasing ejection fraction (EF) (log rank test for trend, chi(2) = 534.5, 1, P < 0.0001). CONCLUSION: The ECHOES mortality data confirm the poor prognosis of patients suffering prevalent HF across the community with a mortality risk estimate of 9% per year. Borderline systolic dysfunction (EF 40-50%) on echocardiography carries a poor prognosis.
Authors: Christopher R deFilippi; Robert H Christenson; Willem J Kop; John S Gottdiener; Min Zhan; Stephen L Seliger Journal: J Am Coll Cardiol Date: 2011-09-27 Impact factor: 24.094
Authors: Gerald S Bloomfield; Allison K DeLong; Constantine O Akwanalo; Joseph W Hogan; E Jane Carter; Daniel F Aswa; Cynthia Binanay; Myra Koech; Sylvester Kimaiyo; Eric J Velazquez Journal: Glob Heart Date: 2016-03
Authors: Bosco Baron-Franco; Gary McLean; Frances S Mair; Veronique L Roger; Bruce Guthrie; Stewart W Mercer Journal: Br J Gen Pract Date: 2017-04-10 Impact factor: 5.386
Authors: Robert J Goldberg; Jerry H Gurwitz; Jane S Saczynski; Grace Hsu; David D McManus; David J Magid; David H Smith; Alan S Go Journal: Am J Cardiol Date: 2013-02-01 Impact factor: 2.778